We scan new podcasts and send you the top 5 insights daily.
Tumors can overexpress Cyclin E1 protein without genomic CCNE1 amplification, driving chronic G1/S progression and replication stress. This leaves malignant cells strictly dependent on the G2/M checkpoint for survival, where WEE1 inhibitors like azenosertib demonstrate promising 30% to 35% response rates in clinical evaluation.
Every cancer specimen is genetically unique, yet all share common traits like uncontrolled division and co-opting normal cell survival mechanisms. The key to treatment is finding pathways that are different enough from normal cells to target and exploit.
Despite immunotherapy's success in other lung cancers, it is completely ineffective for patients with ROS1 fusions. A large global data series showed a 0% response rate. These genetically-driven cancers are "cold tumors," making upfront genomic testing critical to avoid futile and toxic treatment with checkpoint inhibitors.
The novel DiviTum TKA assay measures cell proliferation in real-time. Patterns of TKA level suppression, rebound, or lack of suppression within the first month of CDK4/6 inhibitor therapy strongly predict a patient's long-term progression-free survival, offering an early look at treatment efficacy.
A patient's time to progression on first-line CDK4/6 inhibitor therapy acts as an informal biomarker. A shorter duration, such as 14 months, is viewed by experts as "not so great" and indicates a degree of underlying endocrine resistance that influences subsequent treatment strategies.
Instead of creating therapies for hundreds of specific driver mutations, which vary widely between patients, Earli's platform targets downstream commonalities—the "hallmarks of cancer" like rapid cell proliferation. These pathways are where diverse mutations converge, creating a more universal and reliable target across different cancers.
Targeting GSPT1 is highly effective because its degradation disrupts the production of a specific subset of proteins critical to cancer. This simultaneously reduces levels of key drivers like MYC, androgen receptor (AR), and Cyclin D1, creating a powerful multi-target effect from a single drug.
The sharp early decline on progression-free survival (PFS) curves for oral SERD monotherapy trials indicates that 40-50% of patients have resistance mechanisms beyond just an ESR1 mutation. This highlights the need for better patient selection for monotherapy versus combination approaches to overcome this multifaceted resistance.
Nearly 100% of patients on first-generation CDK4/6 inhibitors develop resistance. This occurs because CDK2, a related 'sibling' kinase, eventually compensates for the inhibited kinases and takes over their function. This predictable mechanism highlights the need for therapies that can safely inhibit all three kinases simultaneously.
Up to a third of CDK inhibitor resistance cases show no known DNA mutations. Dr. Wander suggests epigenetic factors, like DNA methylation altering chromatin architecture, are responsible. These "dark matter" events turn genes on or off without changing the DNA code, requiring new blood-based profiling technologies to detect and understand resistance.
New CDK inhibitors that also target CDK2 show great activity in models resistant to current CDK4/6 agents. Instead of being reserved for later use, they are already being tested in frontline trials. The strategy, similar to that of ALK inhibitors in lung cancer, is that using the best drug first may prevent or significantly delay the onset of resistance.